With regulatory filings now under review in the US, EU and Japan for baricitinib, an oral, selective JAK1/2 inhibitor, Eli Lilly & Co. sees a chance to position the drug in the competitive rheumatoid arthritis space after generic methotrexate therapy but before use of tumor necrosis factor inhibitors.
With Baricitinib, Lilly Hopes To Succeed Where Pfizer Has Struggled
With data demonstrating superiority to Humira and likely lower pricing than anti-TNF drugs, baricitinib may be poised to make more of an impact than Pfizer has with its JAK inhibitor Xeljanz.